Kiwa Bio-Tech & Hebei Huaxing Pharmaceuticals Co., Ltd form Hebei Kiwa Huaxing Bio-Pharmaceuticals Co., Ltd.
BEIJING and CLAREMONT, Calif., May 27 /Xinhua-PRNewswire-FirstCall/ -- Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT) announced entry into a contract for a joint venture named Hebei Kiwa Huaxing Bio-Pharmaceuticals Co., Ltd. The joint venture company aims at developing and producing Kiwa’s AF-01 anti-viral preventative for avian flu. Kiwa Bio-Tech and Hebei Huaxing Pharmaceuticals Co., Ltd. (“Huaxing”) held a ceremony recognizing their cooperation on May 22, 2008.
Under the terms of the contract, Kiwa Bio-Tech owns 70% of the equity of the joint venture and Huaxing owns 30%. For more details about the contract, please refer to 8-K filed with the SEC.
Mr. Ruijun Li, General Manager of Huaxing, noted, “The combination of our companies’ marketing network, technology, manufacturing expertise is expected to support the growth of the joint venture.”
Mr. Wei Li, Chairman and CEO of Kiwa, stated, ‘‘we are pleased that Kiwa will now be able to aggressively pursue commercial development of AF-01 and veterinary pharmaceuticals as the third segment of its business. Now along with continued growth of bio-feed and rapid expansion of bio-fertilizers, Kiwa will be able to manufacture and market AF-01 Anti-viral Aerosol.”
ABOUT AF-01 ANTI-VIRAL AEROSOL
In May 2006 Kiwa acquired AF-01 Anti-viral Aerosol technology for veterinary medicine applications including the exclusive production right and other related rights to produce an anti-viral aerosol drug for use with animals from Jinan Kelongboao Bio-Tech Co., Ltd. ("JKB"), which is affiliated with Chinese Academy of Medical Sciences. The AF-01 aerosol technology is a broad-spectrum anti-viral agent with potent inhibitory and/or viricidal effects on a variety of RNA viruses found in animals and fowls such as bird flu. Kiwa’s hope is to develop a commercialized product in the form of a spray for applying in fowl houses and other animal holding facilities to prevent and cure virus-caused diseases, for example, avian flu and foot-and-mouth disease.
ABOUT HUAXING
Huaxing was founded in 1996. Huaxing is supported by animal husbandry and veterinary medicine agencies at both provincial and municipal levels. Huaxing has focused on building strong co-operative relationships with academic institutions such as the Agricultural University of Heibei and Hebei University of Science & Technology. Huaxing has developed: 12-series of animal medicines and disinfectants, over 200 products for flocks and herds, pigs, furry animals and pets. Huaxing holds 61 approval document numbers for veterinary drug products. Huaxing was inspected by the Ministry of Agriculture of the People’s Republic of China (“Ministry of Agriculture”) and was awarded the GMP qualification in January 2005. Huaxing’s distribution channel covers all of China with exception of Taiwan and Tibet. Huaxing has become a modern high-tech veterinary drug enterprise recognized as a strong force in R&D, manufacturing and also distribution.
ABOUT KIWA BIO-TECH PRODUCTS GROUP CORPORATION
The Company develops, manufactures, distributes and markets innovative, cost-effective, and environmentally safe bio-technological products for agricultural and natural resources and environmental conservation. The Company’s products are designed to enhance the quality of human life by increasing the value, quality and productivity of crops and decreasing the negative environmental impact of chemicals and other wastes. For more information about the Company, please review documents filed with the SEC (www.sec.gov) or visit the Company’s website at http://www.kiwabiotech.com .
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from any future results described by the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date subsequent to the date of this press release.
For more information, please contact:
Kiwa Bio-Tech Products Group Corporation
Yvonne Wang
Tel: +1-626-715-5855
Email: kiwabiotech@gmail.com
Robert Schechter
Equity Communications
Tel: +1-212-499-6809
Email: ir4kiwa@hotmail.com
